Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AbbVie
AbbVie
Skyrizi goes sky-high in October among Rx, OTC pharma brands
Medical Marketing and Media
Sun, 11/12/23 - 09:19 pm
Boehringer Ingelheim
AbbVie
Skyrizi
DTC advertising
pharma advertising
FDA Accepts sBLA for Interchangeability Designation for Humira biosimilars
Dermatology Times
Wed, 11/8/23 - 09:55 pm
Samsung Bioepis
Organon
FDA
AbbVie
Humira
biosimilars
AbbVie, AstraZeneca, Boehringer and more face FTC's ire for 'improper' patent listings
Fierce Pharma
Tue, 11/7/23 - 11:08 pm
FTC
Orange Book
patents
AbbVie
AstraZeneca
Boehringer Ingelheim
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
Fierce Biotech
Sun, 10/29/23 - 08:56 pm
AbbVie
Daiichi Sankyo
Merck
antibody-drug conjugate
AbbVie Stock Dives As Aesthetics Sales Mar Its Third-Quarter Beat And Guidance Boost
Investors Business Daily
Fri, 10/27/23 - 11:51 am
AbbVie
earnings
aesthetics
Humira
biosimilars
AbbVie and Lupus Therapeutics partner for SLE trial recruitment
Clinical Trials Arena
Wed, 10/25/23 - 09:40 am
AbbVie
Lupus Therapeutics
systemic lupus erythematosus
lupus
Rinvoq
clinical trials
Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee
Fierce Pharma
Wed, 10/18/23 - 07:37 pm
Takeda
AbbVie
Shire
M&A
legal
AbbVie trumpets Skyrizi's resounding win against J&J's Stelara in Crohn's disease
Fierce Pharma
Mon, 10/16/23 - 11:50 am
AbbVie
Akyrizi
JNJ
Stelara
Crohn's Disease
AbbVie’s Rinvoq shows long-term sustained efficacy in atopic dermatitis
Clinical Trials Arena
Thu, 10/12/23 - 10:02 am
AbbVie
clinical trials
Rinvoq
atopic dermatitis
FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab
Generics Bulletin
Mon, 10/9/23 - 11:35 pm
Pfizer
Humira
biosimilars
adalimumab
AbbVie
interchangeability
FDA
Months after FDA slam, AbbVie buys Parkinson’s disease drugmaker Mitokinin
Medical Marketing and Media
Thu, 10/5/23 - 09:15 pm
AbbVie
M&A
Mitokinin
Parkinson's Disease
Allergan Aesthetics invests in women’s career trajectories to close STEM gap
Medical Marketing and Media
Tue, 10/3/23 - 07:23 pm
AbbVie
Allergan Aesthetics
women
STEM
Boehringer launches 81% discounted biosimilar of AbbVie's Humira
Reuters
Mon, 10/2/23 - 06:34 pm
Boehringer Ingelheim
biosimilars
AbbVie
Humira
unbranded biosimilars
AbbVie’s venetoclax fails Phase III myeloma trial
Clinical Trials Arena
Mon, 10/2/23 - 10:12 am
AbbVie
venetoclax
Multiple Myeloma
clinical trials
Top Pharma Ad Spenders in August 2023, AbbVie Splurges to Take Top Spots
Xtalks
Sun, 10/1/23 - 01:28 pm
pharma advertising
DTC ads
AbbVie
Skyrizi
Rinvoq
Regeneron
In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset
Fierce Pharma
Fri, 09/29/23 - 12:13 pm
AbbVie
Roche
Venclexta
Multiple Myeloma
AbbVie Terminates Collaboration and License Agreement with Caribou Biosciences
Best Stocks
Tue, 09/26/23 - 10:12 pm
AbbVie
Caribou Biosciences
CRISPR
AbbVie Ends I-Mab Partnership for CD47 Antibody Compounds, Products
BioSpace
Mon, 09/25/23 - 10:04 am
AbbVie
I-Mab Biopharma
Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar
BioSpace
Thu, 09/21/23 - 11:53 am
Alvotech
FDA
biosimilars
AVT02
AbbVie
Humira
Revance rolls out a price drop for Daxxify as it tries to challenge AbbVie's Botox
Fierce Pharma
Wed, 09/20/23 - 08:57 am
Revance Therapeutics
Daxxify
AbbVie
Botox
drug pricing
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »